Literature DB >> 14557222

Aging bone and osteoporosis: strategies for preventing fractures in the elderly.

Mark P Ettinger1.   

Abstract

As the older population increases, the incidence of osteoporotic fractures is expected to dramatically rise during the next few decades. Older patients are much more susceptible to fracture at any given bone mineral density (BMD) than are younger patients because of various factors, including the quality of aging bone, which involves more than BMD. Suppression of increased bone turnover by antiresorptive therapies, even with only small changes in BMD, can reduce fracture risk, especially in the lumbar spine. Bisphosphonate treatment can significantly reduce vertebral and nonvertebral fractures, including hip fractures, even in the very elderly. Prospective analyses show that risedronate therapy consistently and significantly reduces the risk of new morphometric vertebral fractures after 1 year in postmenopausal women. Post hoc analyses report significant reductions in the risk of 1 new clinical vertebral fracture after 6 months of risedronate therapy and after 1 year of alendronate therapy. Oral raloxifene therapy and salmon calcitonin nasal spray therapy have been shown to reduce the risk of vertebral fracture after 3 and 5 years, respectively, and post hoc data show a significant reduction in clinical vertebral fracture risk at 1 year with raloxifene use. However, neither raloxifene therapy nor calcitonin therapy reduce the risk of nonvertebral and hip fractures at currently approved doses. Bisphosphonates have been shown to be safe and efficacious with 7 years' risedronate sodium and 10 years' alendronate sodium data published, and bisphosphonates reduce bone turnover and increase BMD to a greater degree than raloxifene and calcitonin, which may partly account for their nonvertebral and hip fracture reduction effect. Therefore, bisphosphonate therapy with risedronate or alendronate should be considered in patients with low BMD at the hip and in older patients with osteoporosis and osteopenia, particularly those with an existing fracture.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557222     DOI: 10.1001/archinte.163.18.2237

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  41 in total

1.  Percutaneous vertebroplasty in the therapy of osteoporotic vertebral compression fractures: a critical review.

Authors:  K Hochmuth; D Proschek; W Schwarz; M Mack; A A Kurth; T J Vogl
Journal:  Eur Radiol       Date:  2006-03-16       Impact factor: 5.315

Review 2.  Mineral changes in osteoporosis: a review.

Authors:  Dan Faibish; Susan M Ott; Adele L Boskey
Journal:  Clin Orthop Relat Res       Date:  2006-02       Impact factor: 4.176

3.  Three-dimensional image registration of MR proximal femur images for the analysis of trabecular bone parameters.

Authors:  Janet Blumenfeld; Colin Studholme; Julio Carballido-Gamio; Dana Carpenter; Thomas M Link; Sharmila Majumdar
Journal:  Med Phys       Date:  2008-10       Impact factor: 4.071

4.  Transplanted xenogenic bone marrow stem cells survive and generate new bone formation in the posterolateral lumbar spine of non-immunosuppressed rabbits.

Authors:  Hyung-Jun Kim; Jong-Beom Park; Jin Kyung Lee; Eun-Young Park; Eun-Ae Park; K Daniel Riew; Seung-Koo Rhee
Journal:  Eur Spine J       Date:  2008-09-25       Impact factor: 3.134

5.  Strontium Ranelate: Long-Term Efficacy against Vertebral, Nonvertebral and Hip Fractures in Patients with Postmenopausal Osteoporosis.

Authors:  Jean-Yves Reginster; Mickaël Hiligsmann; Olivier Bruyere
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-06       Impact factor: 5.346

6.  Short-term effects of extracorporeal shock wave therapy on bone mineral density in postmenopausal osteoporotic patients.

Authors:  L Shi; F Gao; W Sun; B Wang; W Guo; L Cheng; Z Li; W Wang
Journal:  Osteoporos Int       Date:  2017-07-06       Impact factor: 4.507

7.  Hip fracture risk among community-dwelling elderly people in the United States: a prospective study of physical, cognitive, and socioeconomic indicators.

Authors:  Robin Taylor Wilson; Gary A Chase; Elizabeth A Chrischilles; Robert B Wallace
Journal:  Am J Public Health       Date:  2006-05-30       Impact factor: 9.308

8.  Bisphosphonate Withdrawal: Effects on Bone Formation and Bone Resorption in Maturing Male Mice.

Authors:  Frank C Ko; Lamya Karim; Daniel J Brooks; Mary L Bouxsein; Marie B Demay
Journal:  J Bone Miner Res       Date:  2017-01-17       Impact factor: 6.741

9.  Undertreatment of osteoporosis in the oldest old? A nationwide study of over 700,000 older people.

Authors:  Kristina Johnell; Johan Fastbom
Journal:  Arch Osteoporos       Date:  2009-03-19       Impact factor: 2.617

10.  Closing the osteoporosis care gap: increased osteoporosis awareness among geriatrics and rehabilitation teams.

Authors:  Derek A Haaland; Dana R Cohen; Courtney C Kennedy; Nader A Khalidi; Jonathan D Adachi; Alexandra Papaioannou
Journal:  BMC Geriatr       Date:  2009-07-14       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.